Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Hepatocellular carcinoma (HCC) presents a significant global health challenge with poor survival rates.
• Novel therapeutic strategies are urgently needed for effective HCC treatment.
• The efficacy of gefitinib, an EGFR-TK inhibitor, in HCC remained largely uninvestigated.

Purpose of the Study:

• To investigate the antineoplastic effects of gefitinib on human hepatocellular carcinoma (HCC) cells.
• To determine the impact of gefitinib on HCC cell growth, apoptosis, and cell cycle progression.

Main Methods:

• Treatment of human HCC cell lines (Huh-7 and HepG2) with gefitinib.
• Assessment of cell growth inhibition, apoptosis induction (caspase activation, mitochondrial membrane potential), and cell cycle arrest (G1/S checkpoint).
• Evaluation of mitogen-activated protein kinase (MAPK) pathway and Bcl-2 family protein expression.

Main Results:

• Gefitinib demonstrated dose- and time-dependent inhibition of HCC cell growth.
• Gefitinib induced both mitochondria-dependent and -independent apoptosis, evidenced by caspase activation and nuclear degradation.
• Gefitinib caused G1/S cell cycle arrest and reduced ERK1/2 phosphorylation, suppressing antiapoptotic Bcl-2 and Bcl-X(L) expression.

Conclusions:

• Gefitinib effectively inhibits growth, induces apoptosis, and causes cell cycle arrest in human HCC cells.
• Inhibition of EGFR-TK by gefitinib represents a potential novel therapeutic approach for hepatocellular carcinoma.
• Further research into EGFR-TK inhibitors for HCC treatment is warranted.